Key Takeaways QGEN is expanding key platforms with FDA-cleared panels and new digital PCR assay launches. Strategic deals with Eli Lilly, AstraZeneca, and others are fueling QGEN's diagnostic innovations. QGEN maintains solid solvency, with $638.8M in cash and just$56M in current debt as of Q1 2025.QIAGEN N.V. (QGEN) is well-poised to grow in the upcoming quarters, courtesy of substantial investment in research and development (R&D) for the menu expansion of its key platforms. Expanding through partnersh ...